

# Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS)



GIOVANNI MONTESANO, GIOVANNI OMETTO, ANTHONY KING, DAVID F. GARWAY-HEATH, AND DAVID P. CRABB

- **PURPOSE:** to compare visual field (VF) progression between the 2 arms of the Treatment of Advanced Glaucoma Study (TAGS).
- **DESIGN:** Post hoc analysis of VF data from a 2-arm, multicenter, randomized controlled clinical trial.
- **METHODS:** A total of 453 patients with newly diagnosed advanced open-angle glaucoma in at least 1 eye from 27 centers in the United Kingdom were randomized to either trabeculectomy ( $n = 227$ ) or medication in their index eye ( $n = 226$ ) and followed-up for 2 years with 2 24-2 VF tests at baseline, 4, 12, and 24 months. Data were analyzed for participants with a reliable VF (false positive rate  $< 15\%$ ) at baseline and at least 2 other time points. Average difference in rate of progression (RoP) was analyzed using a hierarchical Bayesian model. Time for each eye to progress from baseline beyond specific cut-offs (0.5, 1, 1.5, and 2 dB) was compared using survival analysis.
- **RESULTS:** This study analyzed 211 eyes in the trabeculectomy first arm and 203 eyes in the medication first arm. The average RoP (estimate [95% credible intervals]) was  $-0.59$  [ $-0.88, -0.31$ ] dB/year in the medication first arm and  $-0.40$  [ $-0.67, -0.13$ ] dB/year in the trabeculectomy first arm. The difference was not significant (Bayesian  $P$ -value = .353). More eyes progressed in the medication first arm, but this difference was not significant.
- **CONCLUSIONS:** There was no significant difference in the average RoP at 2 years. (Am J Ophthalmol 2023;246: 42–50. © 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>))

## INTRODUCTION

THE ONLY CURRENT TREATMENT FOR GLAUCOMA IS reduction of intraocular pressure (IOP).<sup>1-3</sup> Trabeculectomy is the most commonly performed surgical intervention and has been proven to be more effective than medication (drops) in achieving lower IOP.<sup>4</sup> For this reason, clinical guidelines in the UK and Europe suggest that trabeculectomy be offered to patients with advanced glaucoma as the first line of treatment.<sup>5,6</sup> However, no specific guidelines regarding the appropriate timing of surgical intervention exist for North America.<sup>7,8</sup> Evidence to support such recommendations is scant<sup>5</sup> and practitioners are often unkeen to offer surgery owing to possible sight-threatening complications.<sup>5,9</sup> As a result, patients are usually treated with drops and/or laser, and are offered surgery only when initial interventions prove ineffective.

The Treatment of Advanced Glaucoma Study (TAGS) is a recently completed multicenter randomized controlled trial (RCT) comparing medical versus surgical (trabeculectomy) treatments in patients presenting with previously untreated advanced open angle glaucoma.<sup>10-12</sup> The primary outcome was vision-related quality of life (QoL) measured using the Visual Function Questionnaire-25 (VFQ-25). Recently reported results have indicated no difference in this primary outcome between treatment arms for the period of the study (24 months);<sup>11</sup> however, patient self-reported outcome measures have been shown to lack sensitivity in detecting visual deterioration from glaucoma.<sup>13</sup>

Visual field (VF) tests are an important clinical measure in glaucoma<sup>5,7,14</sup> and have been successfully used as a primary outcome in previous important glaucoma trials.<sup>2,3,15-20</sup> In the primary report of results from TAGS, the average difference in VF mean deviation (MD) between baseline and 24 months showed no between-group difference, despite an average 3 mmHg difference in IOP favoring trabeculectomy. However, TAGS was designed such that series of 24-2 VFs (Humphrey Field Analyzer [HFA], Zeiss Meditec) were collected at baseline, 4, 12, and 24 months; the main trial report did not take account of all these data. Previous RCTs<sup>2, 15-20</sup> recognized the importance of analyzing localized change in VF data to detect treatment difference. A recent VF pointwise analysis using a hierarchi-

 Supplemental Material available at [AJO.com](http://ajoo.com).  
Accepted for publication September 20, 2022.

From City, University of London, Optometry and Visual Sciences, London, UK (G.M., G.O., D.P.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK (G.M., D.F.G.-H.); Department of Ophthalmology, Nottingham University Hospital, Nottingham, UK (A.K.)

Inquiries to David P. Crabb, City, University of London, Northampton Square, London, EC1V 0HB, UK; e-mail: [david.crabb.1@city.ac.uk](mailto:david.crabb.1@city.ac.uk)

cal approach for estimating rate (speed) of VF loss in data from the Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) showed differences in the treatment arms unseen in the primary QoL measure used in that trial.<sup>21</sup> The statistical methods used in the LiGHT VF analysis have recently been validated and expanded to account for these features and to maximally exploit the pointwise data from individual locations in the VF.<sup>22</sup> The current study applied these methods to the serial VF data from TAGs, with the objective of identifying whether there is a treatment difference between the study arms unseen in the primary outcome.

---

## METHODS

• **PARTICIPANTS:** The TAGs was a multicenter RCT involving 27 centers across the United Kingdom. The study was approved by the East Midlands – Derby Research Ethics Committee (reference number 13/EM/0395) and adhered to the tenets of the Declaration of Helsinki. Details of the study protocol have been reported elsewhere.<sup>10,23</sup> Briefly, the study recruited patients with a new diagnosis of advanced open angle glaucoma, according to the Hodapp–Parrish–Anderson classification<sup>24</sup> of VF damage, including pigment dispersion, pseudoexfoliative and normal tension glaucoma, in one or both eyes. Exclusion criteria were angle closure or other forms of secondary glaucoma, inability to undergo surgery, and high-risk of trabeculectomy failure (patients with a history of complicated cataract surgery or previous surgery involving violation of the conjunctiva, including vitreoretinal procedures). Participants were randomized to receive either trabeculectomy (augmented with Mytomicin C) or medical management as their first intervention. If both eyes were eligible, the less affected eye, according to the 24-2 HFA MD at baseline, was selected as the index eye and analyzed, but both eyes received the same treatment. This choice was made to give patients with bilateral advanced glaucoma randomized to surgery the best chance of preserving vision in their better eye, as surgery was first performed on the index eye. For participants randomized to trabeculectomy, medical treatment was initiated until surgery was performed (ideally within 3 months). Medication for participants randomized to medical treatment was escalated according to the NICE guidelines,<sup>5</sup> based on clinical judgment. If medical treatment was deemed inadequate, augmented trabeculectomy was offered. Participants were followed up for 24 months for the primary endpoint. Clinical examinations included HFA VF testing (SITA Standard 24-2 testing grid), visual acuity, Goldmann applanation tonometry for IOP measurement, and assessment for complications of treatment and the need for cataract surgery. The study recruited 453 participants (227 randomized to trabeculectomy). Baseline demographics of the sample have previously been described.<sup>11</sup> Relevant characteristics are reported in [Table 1](#).

• **VISUAL FIELD DATA:** Two VF tests were performed at each trial visit at baseline, 4, 12, and 24 months; therefore, each trial participant was scheduled to have a series of 8 VFs, giving a total of 3624 planned VF test. Printouts were scanned by the individual centers and stored in a central repository at the clinical trials unit of the University of Aberdeen. For this study, scans were sent to City, University of London for digitization under a data transfer agreement. The pointwise sensitivity thresholds and false positive (FP) rates were digitized using a bespoke optical character recognition algorithm and independently checked by 2 graders (G.M. and G.O.). The study was able to digitize 3266 (90%) VFs from 452 patients (226 per arm). The remaining VFs were either not performed or not provided by the centers. Data were only analyzed from participants for whom at least 3 reliable VFs from at least 3 different time points, including 1 at baseline, were available. Reliability was defined as FPs < 15%, as this has been shown to be the only reliable indicator of VF performance.<sup>25</sup> The final selection (see flowchart in Supplementary Material Figure S1) included 414 (91%) participants, 211 randomized to have trabeculectomy first. Of these, 22 did not actually receive surgery and continued their treatment with drops. For the final selection, the median [interquartile range] number of VFs per patient was 8 [5-8] for both trial arms.

• **STATISTICAL ANALYSIS:**

*Main outcome*

The primary outcome measure for this work was the difference in overall rate of progression (RoP [dB/year]) of VF damage between the 2 trial arms in the index eye. The RoP was estimated using a hierarchical mixed effect model described in detail elsewhere.<sup>26</sup> In short, the response variable was the point-wise sensitivity (in dB) over time (ie, at each location). Time from baseline (in years) and the treatment allocation arm (coded as a binary discrete factor) were used as fixed effects. The interaction between these fixed effects modelled the difference in progression rate between the 2 arms (main outcome of interest). Observations were then grouped by location, VF cluster, and eye in a hierarchical nested fashion, as previously described.<sup>26</sup> Clusters were defined according to Garway-Heath and associates.<sup>27</sup> The method also accounts for the measurement floor at 0 dB by censoring the observations where no response was recorded (< 0 dB on the VF printout), as considering these observations as actual 0 dB measurements can introduce a bias in the estimated RoPs.<sup>26</sup>

These models are complex to estimate with maximum likelihood methods; therefore, R (R Foundation for Statistical Computing) and JAGS (Just Another Gibbs Sampler<sup>28</sup>) were used to estimate the parameters through Bayesian computation, as previously described.<sup>26</sup> Details of the computation are provided as Supplementary Material. Bayesian computation does not produce *P*-values; however, a similar metric, with little difference in interpretation, is derived

**TABLE 1.** Baseline Characteristics of the Cohort Recruited for the Trial.

	Medication First (n = 226)	Trabeculectomy First (n = 227)
<b>Mean (SD) age, years</b>	68 (12.4)	67 (12.2)
<b>Male sex</b>	147 (65)	156 (69)
<b>Ethnicity</b>		
White	191 (85)	182 (80)
Afro-Caribbean	27 (12)	32 (14)
Asian – India/Pakistan/Bangladesh	4 (2)	8 (4)
Asian – Oriental	0 (0)	2 (1)
Mixed heritage	1 (< 1)	0 (0)
Other	2 (1)	3 (1)
Missing	1 (< 1)	0 (0)
<b>Glaucoma diagnosis</b>		
Primary OAG (including NTG)	220 (97)	219 (96)
Pigment dispersion syndrome	4 (2)	5 (2)
Pseudoexfoliation syndrome	2 (1)	3 (1)
<b>Lens status</b>		
Phakic	209 (92)	212 (93)
Pseudophakic	17 (8)	15 (7)
<b>Mean (SD) central corneal thickness, <math>\mu\text{m}</math></b>	541 (36); n = 223	539.4 (36); n = 226
<b>Glaucoma medications at baseline</b>		
Prostaglandin analogue	182 (81)	186 (82)
$\beta$ -blocker	52 (23)	52 (23)
Carbonic anhydrase inhibitor	33 (15)	45 (20)
$\alpha$ agonist	4 (2)	7 (3)
Diamox (taken orally)	2 (1)	6 (3)
<b>Ocular comorbidity</b>	50 (22)	50 (22)
Age-related macular degeneration	4 (8)	6 (12)
Cataract	42 (84)	42 (84)
Vascular occlusion	1 (2)	2 (4)
Diabetic retinopathy	1 (2)	1 (2)
Other	6 (12)	9 (18)
<b>Mean (SD) VFMD, dB</b>	-15.26 (6.34)	-14.91 (6.36)
<b>Mean (SD) logMAR visual acuity</b>	0.17 (0.26); n = 223	0.15 (0.25)
<b>Mean (SD) intraocular pressure, mm Hg</b>		
At diagnosis	25.9 (8.4); n = 223	26.9 (9.1); n = 226
At baseline	19.0 (5.7); n = 221	19.4 (6.2); n = 222

Data reported as number (percentage) unless otherwise indicated. logMAR = logarithm of the minimum angle of resolution; NTG = normal tension glaucoma; OAG = open angle glaucoma; SD = standard deviation; VFMD = visual field mean deviation.

from the Bayesian P-direction<sup>29</sup>. This index was denoted as  $P_d$ , while  $P$  was reserved for the conventional frequentist  $P$ -value. For both metrics, the threshold for statistical significance was .05.

Analysis was performed using both the original randomization (intention-to-treat) and the actual treatment received (analysis by treatment received), since 22 patients randomized to trabeculectomy were kept on medical treatment and did not undergo surgery. Finally, the analysis was also repeated with standard maximum likelihood (ML) methods (*lme4* package for R<sup>30</sup>) using a simplified model that did not account for censoring and VF clusters (results reported in Supplementary Material).

No power or sample size calculation was performed because these were all post hoc analyses of trial data.

### Secondary outcomes

The primary analysis was repeated using the VF clusters as fixed effects (details in Supplementary Material) so that the mean regional baseline VF damage and RoPs could be explicitly modelled and compared. Other analyses, listed below, were performed by fitting individual hierarchical models to each eye, as previously described<sup>26</sup> (ie, each eye was modelled in isolation independently of their randomization) to assess how treatment affected individual patients and localized progression.

- *Time to visual field progression*: for each eye, a progression event was defined as an estimated global change from baseline by more than 4 pre-defined cut-off values (0.5, 1, 1.5, and 2 dB) over the observation period. The time to the event (in years) was estimated as cut-off/RoP and

**TABLE 2.** Population Estimates [95% Credible Intervals] for the Visual Field Baseline Damage and Rate of Progression, Globally and by Garway-Heath Cluster.

		Medication First	Trabeculectomy First	Difference	$P_d$
<b>Intention-to-treat</b>					
<b>Global</b>	<b>Baseline (dB)</b>	14.24 [13.19, 15.25]	14.10 [13.10, 15.11]	-0.13 [-1.55, 1.31]	0.857
	<b>RoP (dB/year)</b>	-0.59 [-0.88, -0.31]	-0.40 [-0.67, -0.13]	0.19 [-0.20, 0.58]	0.353
<b>Cluster 1</b>	<b>Baseline (dB)</b>	9.52 [8.03, 11.01]	9.83 [8.40, 11.32]	0.31 [-1.86, 2.39]	0.769
	<b>RoP (dB/year)</b>	-0.58 [-0.99, -0.18]	-0.47 [-0.87, -0.07]	0.11 [-0.45, 0.66]	0.717
<b>Cluster 2</b>	<b>Baseline (dB)</b>	7.69 [6.08, 9.39]	8.36 [6.76, 9.94]	0.67 [-1.66, 2.97]	0.559
	<b>RoP (dB/year)</b>	-0.81 [-1.20, -0.40]	-0.41 [-0.79, -0.03]	0.39 [-0.16, 0.93]	0.159
<b>Cluster 3</b>	<b>Baseline (dB)</b>	18.79 [17.71, 19.85]	18.89 [17.82, 19.97]	0.10 [-1.40, 1.62]	0.896
	<b>RoP (dB/year)</b>	-0.78 [-1.08, -0.48]	-0.67 [-0.97, -0.38]	0.10 [-0.31, 0.52]	0.623
<b>Cluster 4</b>	<b>Baseline (dB)</b>	15.60 [14.00, 17.17]	14.87 [13.23, 16.50]	-0.73 [-3.04, 1.50]	0.543
	<b>RoP (dB/year)</b>	-0.70 [-1.03, -0.37]	-0.37 [-0.70, -0.04]	0.33 [-0.14, 0.79]	0.162
<b>Cluster 5</b>	<b>Baseline (dB)</b>	15.40 [13.93, 16.93]	14.50 [12.98, 15.95]	-0.90 [-3.04, 1.13]	0.404
	<b>RoP (dB/year)</b>	-0.45 [-0.77, -0.13]	-0.24 [-0.57, 0.09]	0.21 [-0.25, 0.68]	0.368
<b>Cluster 6</b>	<b>Baseline (dB)</b>	19.14 [17.96, 20.34]	18.82 [17.64, 20.02]	-0.32 [-1.98, 1.38]	0.698
	<b>RoP (dB/year)</b>	-0.15 [-0.53, 0.22]	-0.30 [-0.67, 0.07]	-0.14 [-0.68, 0.38]	0.590

Note that the baseline is reported as the intercept of the models. Cluster 1 = peripheral superior; Cluster 2 = paracentral superior; Cluster 3 = central; Cluster 4 = paracentral inferior; Cluster 5 = peripheral inferior; Cluster 6 = temporal (see also Figure 2). RoP = rate of progression.

censored at the last actually observed time point. A Cox proportional hazard model was used to compare the 2 arms at each cut-off. Note that, for this analysis, all data in the series were used to estimate when the event occurred; this improved accuracy, as events could be detected in between visits, and reduced the impact of noise fluctuations.

- *Time to convert to perimetric blindness for each location:* estimates of time to cross the 0 dB sensitivity threshold were obtained for each location in each eye from the fitted slopes and intercepts. This analysis was limited to locations with an estimated intercept > 0 dB at baseline. A Cox proportional hazard model was used to compare the 2 arms. Correlations among locations from the same eyes were accounted for using a robust variance estimation and a cluster term (*survival* package in R<sup>31</sup>). The comparison was limited to the actual observation time. To evaluate the impact on central vision the same analysis was repeated by only considering the 12 locations within the central 10 degrees.
- *Local progression rate:* Finally, the RoP of the fastest progressing cluster and the 5 fastest locations with intercept > 0 dB were extracted for each eye. The distribution of the RoP of the fastest cluster and of the average RoP of the 5 fastest locations were compared using a non-parametric test (Mann-Whitney).

A supplementary analysis was also performed to evaluate differences in the distribution of all point-wise slopes. The detailed methodology and results are reported as Supplementary Material.

## RESULTS

- **MAIN OUTCOME:** Eyes in the 2 arms of the study, for both the intention-to-treat and analysis by treatment received, had similar average baseline VF sensitivity as estimated by the intercepts of the model (Table 2), as it would be expected from a RCT. Mean RoP (intention-to-treat) was -0.58 and -0.39 dB per year for the medication first and trabeculectomy first arms, respectively; the 20% difference was not statistically significant ( $P_d = 0.353$ ). Similarly, there was no difference with an analysis by treatment received (RoP -0.55 and -0.43 dB per year for medication first and trabeculectomy first arms, respectively,  $P_d = 0.553$ ). Comparing individual VF clusters (secondary outcome) confirmed these results. The largest difference in mean RoP was recorded for the paracentral superior cluster (Cluster 2) but the effect was still not statistically significant ( $P_d = 0.159$ ). Table 2 reports the results for the intention-to-treat analysis in detail. Results for the analysis by treatment received are reported as Supplementary Material Table S1. Similar results were obtained with standard ML frequentist methods (see Supplementary Material Table S2). Figure 1 graphically shows the average spatial distribution of VF damage at baseline and RoP for the 2 arms.

- **SECONDARY OUTCOMES:** In the intention-to-treat analysis, a higher proportion of eyes showed a change from baseline in the medication first arm (Figure 2) but significance was not reached for any of the cut-offs. Similar results were obtained when performing the analysis by treatment




FIGURE 1. Average baseline damage and rate of progression for each location and Garway-Heath cluster. Unlike the estimates reported in Table 2, these plots are produced by averaging estimates from fits on individual eyes.

received (Supplementary Material Figure S2). No statistically significant difference in the time to perimetric blindness could be found in the intention-to-treat analysis either when examining the whole VF ( $P = .079$ ) or just the central 10 degrees ( $P = .096$ ). Similar results were found in the analysis by treatment received (whole VF:  $P = .191$ ; central 10 degrees:  $P = .218$ ). Further details are reported in Supplementary Material Figure S5. There was no statistically significant difference in the distribution of the average RoP of the 5 fastest progressing locations or the fastest progressing cluster (see Figure 3).

## DISCUSSION

The main outcome did not show any statistically significant difference in the rate of VF progression in patients randomized to trabeculectomy first compared with medication first after 24 months of follow-up. Possible differences in localized progression were also explored by analyzing the average progression rate for different VF clusters, by comparing the RoP of the fastest cluster and the average RoP of the 5 fastest locations in each eye, and by comparing the





FIGURE 2. Estimated time to observe a change from baseline for different cut-offs. *P*-values were calculated with a proportional hazard model. Cross marks indicated censored data.

time to estimated perimetric blindness of individual locations. These comparisons all failed to reach significance. Finally, a higher percentage of eyes progressing beyond specific cut-offs from baseline sensitivity were found, indicating lower frequency of progressive VF loss in eyes receiving trabeculectomy first, but these differences were not statistically significant.

This work is novel because it provides a detailed evaluation of VF progression in patients with advanced glaucoma having primary medical or surgical intervention in an RCT. Differences in RoP between the treatment arms of

the trial were quantified through a hierarchical model able to fully exploit the information from individual locations in the VF. Moreover, this model accounted for the censoring of VF data at 0 dB, avoiding the floor effect, which may cause positive bias in the estimated RoP, especially with advanced VF loss.<sup>26</sup> The secondary analyses evaluated progression in different VF clusters, localized progression, and point-wise conversion to perimetric blindness (estimated sensitivity < 0 dB).

Taken together, the main results suggest equivalence in terms of progression of VF damage between the two treat-



**FIGURE 3.** Comparison of the rate of progression for the fastest cluster and the average of the five fastest locations for each eye. Estimates obtained from individual fits on each eye. *P*-values obtained with a Mann–Whitney test.

ment approaches within the first 2 years after initiating treatment, but there is also evidence to suggest that the small observed difference might increase in the future. This is consistent with the main results of the trial,<sup>11</sup> which showed no difference in vision-related QoL between the 2 arms at the 2-year time point; these results are clinically important and may reflect the differences observed in the control of the IOP between the 2 arms.<sup>11</sup>

More indications of a possible difference come from the secondary VF analyses. The time to VF progression (Figure 2) showed a higher proportion of progressors in the medication first arm. These differences did not reach significance. Some significant differences emerged without considering censoring at 0 dB (Supplementary Material Figure S3 and S4). This analysis is key to understanding the effect of treatment on individual patients rather than the average effect across the cohort. This result is in partial agreement with similar previous randomized clinical trials comparing primary medical and surgical treatment, such as the Collaborative Glaucoma Intervention Study (CIGTS),<sup>32</sup> which reported marginally (4%) more progressing eyes in patients with early glaucoma in the medication first arm compared with the trabeculectomy first arm. However, later analyses of the same cohort showed a significant difference in MD between the 2 arms of the trial for patients with advanced baseline damage at 7 and 9 years, despite not showing any significant difference up to 5 years.<sup>20</sup> Similarly, the small differences in the average RoP observed in the current cohort might amplify over a longer follow-up period. Similar results were obtained by analyzing progression of individual clusters and locations. One relevant observation from the evaluation for this cohort of patients was that the number of locations converting to perimetric blindness (estimated

sensitivity < 0 dB) was slightly higher for the medication first arm; however, the difference was not statistically significant. Finally, no statistically significant difference could be found in local progression, tested by examining the rate of the fastest progressing cluster and the average RoP of the 5 fastest progressing locations for each eye. This analysis enabled differences in progression rates to be examined in the regions of most rapidly progressing VF, which might not be well captured by the main analysis on the difference in mean RoP. A similar approach was found to be useful when analyzing VF data from LiGHT,<sup>22</sup> in which most of the difference between the 2 arms of the trial was located in the extreme negative tails of the distributions of pointwise progression slopes. An additional analysis, more akin to the one performed by Wright and associates,<sup>22</sup> is reported as Supplementary Material (Figure S6).

This analysis had limitations: (1) the limited follow up time (2 years) was short in the context of a median life expectancy at diagnosis of around 14 years<sup>33</sup> and this made identification of statistically significant differences challenging, especially with advanced damage<sup>34,35</sup> because it is well known that VF variability increases with the amount of damage.<sup>25</sup> A relatively small difference in progression rates between treatment arms was expected because all patients are treated to low IOPs in advanced glaucoma. The IOP reduction achieved in both arms of TAGS was about 3 mmHg greater than that achieved in CIGTS.<sup>32</sup> The increased test variability was partially addressed by having 2 repetitions of the VF test at each time point and the use of a trend analysis over an event-based analysis. The modelling technique also eliminated the bias introduced by the floor effect at 0 dB;<sup>26</sup> however, it could not overcome the fact that many locations would provide limited information, being

at or very close to the 0 dB limit. One possibility for future trials could be to test these patients with macular testing patterns, such as the 10-2. The time-to-progression estimates might have also been influenced by the effect of developing cataract. Non-glaucoma-related changes in vision from a treatment should also be considered as part of the effect, as they can negatively impact QoL. Lens opacity was not graded in the trial; however, the number of patients needing cataract surgery was not different between the 2 arms (12% for the medication first arm and 13% for the trabeculectomy first arm).<sup>11</sup> Still, a small significant difference was found in logMAR visual acuity at 24 months (0.07, 95% CI 0.02-0.11;  $P = .006$ ),<sup>11</sup> possibly indicating more lens opacity in the trabeculectomy first arm. This could have caused non-glaucomatous VF worsening in the trabeculectomy first group, reducing the measured differences between the 2 arms. Metrics that correct for generalized loss, such as pattern deviation maps, are not appropriate for

quantifying advanced glaucomatous damage<sup>36,37</sup> and were therefore not considered for this analysis. However, in a study of glaucoma patients undergoing cataract surgery, visual acuity improved by 0.17 logMAR, yet there was a negligible impact on the VF with a difference in MD of 0.06 dB.<sup>38</sup> Therefore, it is thought to be unlikely that developing cataract greatly influenced the difference between the treatment groups. One important final note is that lack of a significant difference does not necessarily indicate equivalence. This is especially true for the current results, where many non-significant  $P$ -values were smaller than .1, and this should be considered when interpreting the results. Finally, most patients included in TAGS were Caucasian, and this might limit generalizability to other populations. Future investigations will focus on the specific role of IOP control and other relevant baseline characteristics of disease progression in TAGS.

**Funding/Support:** The project was funded by the NIHR Health Technology Assessment Programme (Project Number 12/35/38). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing the report, or decision to submit the article for publication. **Financial Disclosures:** **GM:** consultant for CenterVue Revenio, Omikron, and Ivantis; grant recipient from Santen; vested interests in Relayer, Ltd. **GO:** consultant for Ivantis and Precision vision; vested interests in Relayer, Ltd. **DGH:** consultant for Allergan, Bausch & Lomb, CenterVue Revenio, Genentec, Janssen, Omikron, Roche, and Santen; grant recipient from Alcon Research Institute, Janssen, Santen, and Novartis; research equipment from Centervue Revenio, Heidelberg Engineering, Oculus, and Topcon. **AK:** payments for lectures and spokesperson from Glaukos, Thea, and Allergan. **DC:** consultant for Allergan, Apellis, Roche, Santen, Centervue Revenio, and Thea; grant recipient from Allergan, Apellis, CenterVue Revenio, and Santen. **Conflict of Interests:** All authors have completed and submitted the ICMJE disclosures form. There are no conflict of interests specifically pertaining to this work.

**TAGS Study Group:** Anthony King, Pavi Agrawal, Richard Stead, David C Broadway, Nick Strouthidis, Shenton Chew, Chelvin Sng, Marta Toth, Gus Gazzard, David Garway-Heath, Keith Barton, Ahmed Elkarmouty, Eleni Nikita, Giacinto Triolo, Soledad Aguilar-Munoz, Saurabh Goyal, Sheng Lim, Velota Sung, Imran Masood, Nicholas Wride, Amanjeet Sandhu, Elizabeth Hill, John Sparrow, Fiona Grey, Rupert Bourne, Gnanapragasam Nithyanandarajah, Catherine Willshire, Philip Bloom, Faisal Ahmed, Francesca Cordeiro, Laura Crawley, Eduardo Normando, Sally Ameen, Joanna Tryfinopoulou, Alistair Porteous, Gurjeet Jutley, Dimitrios Bessinis, James Kirwan, Shahiba Begum, Anastasios Sepetis, Edward Rule, Richard Thornton, Andrew McNaught, Nitin Anand, Anil Negi, Obaid Kousha, Marta Hovan, Roshini Sanders, Pankaj Kumar Agarwal, Andrew Tatham, Leon Au, Cecelia Fenerty, Tanya Karacanjic, Brett Drury, Duya Penmol, Ejaz Ansari, Albina Dardzhikova, Reza Moosavi, Richard Imonikhe, Prodromos Kontovourikis, Luke Membrey, Goncalo Almeida, James Tildsley, Augusto Azuara-Blanco, Angela Knox, Simon Rankin, Sara Wilson, Avinash Prabhu, Subhanjan Mukherji, Amit Datta, Alisdair Fern, Joanna Liput, Tim Manners, Josh Pilling, Clare Stemp, Karen Martin, Tracey Nixon, Caroline Cobb, Alan Rotchford, Sikander Sidiki, Atul Bansal, Obaid Kousha, Graham Auger, Mary Freeman, Gordon Fernie, Alison MacDonald, Ashleigh Kernohan, Jennifer Burr, Tara Homer, Hosein Shabaninejad, Luke Vale, John Norrie.

In the Treatment for Advanced Glaucoma Study (TAGS), trabeculectomy as first treatment did not significantly reduce the average global progression in advanced glaucoma at 2 years compared with medical treatment, but significantly reduced the proportion of progressing eyes.

## REFERENCES

1. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. *BMJ*. 2005;331:134.
2. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet*. 2015;385:1295–1304.
3. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. *Am J Ophthalmol*. 2000;130:429–440.
4. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. *Cochrane Database Syst Rev*. 2012:CD004399.
5. Excellence NIHaC. *Glaucoma: diagnosis and management*. London: NICE guideline [NG81]; 2017.
6. European Glaucoma Society Terminology and Guidelines for Glaucoma 4th Ed. Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. *Br J Ophthalmol*. 2017;101:130–195.
7. Ophthalmology AAo. *Primary Open Angle Glaucoma: Preferred Practice Patterns*. Elsevier Inc; 2015.
8. Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert C, Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. *Can J Ophthalmol*. 2009;44(Suppl 1):S7–S93.
9. Stead R, Azuara-Blanco A, King AJ. Attitudes of consultant ophthalmologists in the UK to initial management of glaucoma patients presenting with severe visual field loss: a national survey. *Clin Exp Ophthalmol*. 2011;39:858–864.

10. King AJ, Fernie G, Azuara-Blanco A, et al. Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol. *Br J Ophthalmol*. 2018;102:922–928.
11. King AJ, Hudson J, Fernie G, et al. Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS). *BMJ*. 2021;373:n1014.
12. King AJ, Fernie G, Hudson J, et al. Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT. *Health Technol Assess*. 2021;25:1–158.
13. Jones L, Garway-Heath DF, Azuara-Blanco A, Crabb DP. United Kingdom Glaucoma Treatment Study I. Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as End Points in Clinical Trials?: Evidence from the United Kingdom Glaucoma Treatment Study. *Ophthalmology*. 2019;126:682–689.
14. Society EG. *Terminology and Guidelines for Glaucoma*. 5th ed. Italy: Publicomm; 2020.
15. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol*. 2002;120:701–713; discussion 829–830.
16. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol*. 2002;120:1268–1279.
17. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. *Am J Ophthalmol*. 1998;126:487–497.
18. Anderson DR. Normal Tension Glaucoma S. Collaborative normal tension glaucoma study. *Curr Opin Ophthalmol*. 2003;14:86–90.
19. Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. *Ophthalmology*. 2005;112:366–375.
20. Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK, Investigators CS. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. *Ophthalmology*. 2009;116:200–207.
21. Artes PH, Iwase A, Ohno Y, Kitazawa Y, Chauhan BC. Properties of perimetric threshold estimates from Full Threshold, SITA Standard, and SITA Fast strategies. *Invest Ophthalmol Vis Sci*. 2002;43:2654–2659.
22. Wright DM, Konstantakopoulou E, Montesano G, et al. Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT). *Ophthalmology*. 2020;127:1313–1321.
23. King AJ, Hudson J, Fernie G, et al. Baseline Characteristics of Participants in the Treatment of Advanced Glaucoma Study: A Multicenter Randomized Controlled Trial. *Am J Ophthalmol*. 2020;213:186–194.
24. Hodapp E, Parrish RK, Anderson DR. *Clinical decision in glaucoma*. St Kouis MO: Mosby; 1993.
25. Yohannan J, Wang J, Brown J, et al. Evidence-based Criteria for Assessment of Visual Field Reliability. *Ophthalmology*. 2017;124:1612–1620.
26. Montesano G, Garway-Heath DF, Ometto G, Crabb DP. Hierarchical Censored Bayesian Analysis of Visual Field Progression. *Transl Vis Sci Technol*. 2021;10:4.
27. Garway-Heath DF, Poinosawmy D, Fitzke FW, Hitchings RA. Mapping the visual field to the optic disc in normal tension glaucoma eyes. *Ophthalmology*. 2000;107:1809–1815.
28. Plummer, M. (2003). JAGS: A Program for Analysis of Bayesian Graphical Models Using Gibbs Sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), Vienna, 20-22 March 2003, 1-10.
29. Makowski D, Ben-Shachar MS, Chen SHA, Ludecke D. Indices of Effect Existence and Significance in the Bayesian Framework. *Front Psychol*. 2019;10:2767.
30. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat Software*. 2015;1.
31. Therneau TM. A Package for Survival Analysis in R, 3.2-9 ed, 2021. <https://cran.r-project.org/web/packages/survival/vignettes/survival.pdf>.
32. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. *Ophthalmology*. 2001;108:1943–1953.
33. Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. *Invest Ophthalmol Vis Sci*. 2014;55:102–109.
34. Rui C, Montesano G, Crabb DP, et al. Improving event-based progression analysis in glaucomatous visual fields. *Sci Rep*. 2021;11:16353.
35. Gardiner SK, Swanson WH, Goren D, Mansberger SL, Demirel S. Assessment of the reliability of standard automated perimetry in regions of glaucomatous damage. *Ophthalmology*. 2014;121:1359–1369.
36. Artes PH, Nicolela MT, LeBlanc RP, Chauhan BC. Visual field progression in glaucoma: total versus pattern deviation analyses. *Invest Ophthalmol Vis Sci*. 2005;46:4600–4606.
37. Blumenthal EZ, Sapir-Pichhadze R. Misleading statistical calculations in far-advanced glaucomatous visual field loss. *Ophthalmology*. 2003;110:196–200.
38. Carrillo MM, Artes PH, Nicolela MT, LeBlanc RP, Chauhan BC. Effect of cataract extraction on the visual fields of patients with glaucoma. *Arch Ophthalmol*. 2005;123:929–932.